Revenue Growth Including Income from New Businesses
First written in FY2016-Q3. 15 of 31 entries say "Advanced", first in FY2019. Latest entry: 2026-08-13.
No other company in this theme has enough history to compare yet.
- FY2025AdvancedAnnual report
「Revenue was ¥810 million, up 5.4% from the previous fiscal year.」
Full-year revenue was ¥810 million, up 5.4% from the previous fiscal year, driven by new CDMO projects and Medigen royalty revenue and medical device sales, among other factors. - FY2025-H1AdvancedAnnual report
「Revenue was ¥404 million, up 1.3% year on year.」
Revenue for the six-month accounting period was ¥404 million, up 1.3% year on year. - FY2024-Q2AdvancedAnnual report
「Revenue was ¥399 million, up 14.4% year on year, due to higher sales in the specified cellular products manufacturing business and the CDMO business, among other factors.」
Company-wide revenue was ¥399 million, up 14.4% year on year, driven by higher sales in the specified cellular products manufacturing business and the CDMO business. - FY2024-Q1AdvancedAnnual report
「Revenue for the first quarter was ¥248 million, up 34.1% year on year, due mainly to higher sales in the specified cellular products manufacturing business and the CDMO business.」
Quarterly revenue increased 34.1% year on year due to higher sales in the specified cellular products manufacturing business and the CDMO business, among other factors. - FY2023AdvancedAnnual report
「Revenue was ¥661 million, up 4.4% from the previous fiscal year due to higher sales in the specified cellular products manufacturing business and the CDMO business.」
Full-year revenue was ¥661 million, marking a return to growth with a 4.4% increase from the previous fiscal year. - FY2023-Q3AdvancedAnnual report
「Revenue was ¥491 million, up 4.7% year on year, due to higher sales in the specified cellular products manufacturing business and the CDMO business.」
Revenue was ¥491 million, up 4.7% year on year, driven by higher sales in the specified cellular products manufacturing business and the CDMO business. - FY2023-Q2AdvancedAnnual report
「Revenue was ¥349 million, up 9.8% year on year.」
Revenue increased 9.8% year on year due to higher sales in the specified cellular products manufacturing business and the CDMO business. - FY2023-Q1AdvancedAnnual report
「As a result, the company's operating results for the first quarter were as follows.」
Revenue was ¥185 million, up ¥13 million, or 7.1%, from ¥172 million in the same period of the previous year. - FY2022WorsenedAnnual report
「Revenue was ¥633 million, down 7.2% from the previous fiscal year, as domestic and inbound patient numbers at affiliated medical institutions remained sluggish due to the prolonged COVID-19 pandemic, the recovery in the number of cell processing procedures was limited, and other factors affected results.」
Full-year revenue was ¥633 million, down 7.2% from the previous fiscal year. - FY2022-Q3WorsenedAnnual report
「Revenue was ¥469 million, down 8.3% year on year, as the number of inbound patients at affiliated medical institutions remained sluggish due to the prolonged COVID-19 pandemic, the recovery in domestic patient numbers was limited, and cell processing revenue declined from the same period of the previous year, among other factors.」
Revenue was ¥469 million, down 8.3% year on year, with the revenue decline continuing. - FY2022-Q2AdvancedAnnual report
「Revenue was ¥318 million, up 15.7% year on year, mainly due to efforts to expand new cell processing activities and develop the CDMO business.」
Revenue was ¥318 million, up 15.7% year on year, driven by the expansion of new cell processing activities, development of the CDMO business and other factors. - FY2022-Q1AdvancedAnnual report
「Revenue was ¥172 million, up 23.5% year on year, mainly due to an increase in cell processing revenue resulting from a higher number of cell processing procedures than in the same period of the previous year.」
Revenue was ¥172 million, up 23.5% year on year due to an increase in cell processing procedures and other factors, marking a return to revenue growth. - FY2021-Q3WorsenedAnnual report
「Revenue was ¥512 million, down 19.7% year on year, as the number of inbound patients at affiliated medical institutions remained sluggish following the spread of COVID-19, cell processing revenue declined substantially from the same period of the previous year, and other factors affected results.」
With inbound patient numbers remaining sluggish, revenue was ¥512 million, down 19.7% year on year. - FY2021-Q2WorsenedAnnual report
「Revenue was ¥274 million, down 45.7% year on year, as the number of inbound patients at affiliated medical institutions remained sluggish following the spread of COVID-19, cell processing revenue declined substantially from the same period of the previous year, and other factors affected results.」
Due to the prolonged COVID-19 pandemic and sluggish inbound patient numbers, revenue was ¥274 million, down 45.7% year on year. - FY2021-Q1WorsenedAnnual report
「Revenue was ¥139 million, down 52.7% year on year, as the number of inbound patients at affiliated medical institutions remained sluggish following the spread of COVID-19, cell processing revenue declined substantially from the same period of the previous year, and other factors affected results.」
Due to the prolonged COVID-19 pandemic and sluggish inbound patient numbers, revenue was ¥139 million, down 52.7% year on year. - FY2020-Q3WorsenedAnnual report
「Revenue was ¥637 million, down 15.6% year on year, mainly due to a decline in cell processing revenue resulting from a decrease in the number of inbound patients at affiliated medical institutions following the spread of COVID-19 and other factors.」
Against a backdrop of fewer inbound patients due to COVID-19 and other factors, revenue was ¥637 million, down 15.6% year on year. - FY2020-Q2AdvancedAnnual report
「Revenue was ¥506 million, up 0.9% year on year, mainly due to an increase in cell processing revenue and other factors.」
Revenue for the six-month period was ¥506 million, maintaining revenue growth with a 0.9% year-on-year increase. - FY2020-Q1AdvancedAnnual report
「Revenue was ¥295 million, up 18.8% year on year, mainly due to an increase in cell processing revenue and other factors.」
First-quarter revenue was ¥295 million, marking a return to revenue growth with an 18.8% year-on-year increase. - FY2019AdvancedAnnual report
「As a result, revenue was ¥1,059 million, an increase of ¥101 million, or 10.6%, from the previous fiscal year.」
Full-year revenue after the transition to non-consolidated reporting was ¥1,059 million, an increase of ¥101 million, or 10.6%, from the previous fiscal year according to the company's figures. - FY2019-Q3Revenue disclosed following the transition to non-consolidated reportingAnnual report
「Revenue for the nine-month period was ¥755 million.」
Although no comparison with the same quarter of the previous year was made due to the transition to non-consolidated reporting, revenue of ¥755 million was disclosed for the nine-month period. - FY2018-Q3WorsenedAnnual report
「Revenue was ¥770 million, down ¥544 million, or 41.4%, from the same period of the previous year.」
Revenue for the nine-month period declined 41.4% year on year, widening from the 39.3% decline in Q2. - FY2018-Q2WorsenedAnnual report
「Revenue was ¥542 million, down ¥351 million, or 39.3%, from the same period of the previous year.」
Revenue for the six-month period declined 39.3% year on year, and the decline widened. - FY2018-Q1WorsenedAnnual report
「Revenue was ¥295 million, down ¥156 million, or 34.6%, from the same period of the previous year.」
Revenue declined from ¥451 million in the same period of the previous year to ¥295 million, a decrease of 34.6% year on year. - FY2017WorsenedAnnual report
「Revenue was ¥1,704,004 thousand, down ¥205,319 thousand, or 10.8%, from the previous fiscal year.」
Full-year revenue declined 10.8% year on year, confirming that the revenue decline seen through the quarterly stages continued for the full year. - FY2017-Q3WorsenedAnnual report
「Revenue for the nine-month period ended 31 December was ¥1,314 million, down ¥89 million, or 6.3%, from the same period of the previous year.」
Revenue declined from ¥1,404,001 thousand in the same period of the previous year to ¥1,314,963 thousand, a decrease of 6.3% year on year. - FY2017-Q2WorsenedAnnual report
「Revenue was ¥893 million, down ¥33 million, or 3.6%, from the same period of the previous year.」
Revenue declined from ¥926,955 thousand in the same period of the previous year to ¥893,792 thousand, a decrease of 3.6% year on year. - FY2017-Q1WorsenedAnnual report
「Net sales declined 3.0% year on year, primarily because sales from the core cell-processing business were broadly unchanged from the previous year, while sales of cell-therapy equipment and materials recorded in the previous year declined.」
Revenue declined from ¥465,347 thousand in the same period of the previous year to ¥451,311 thousand, a decrease of 3.0% year on year. - FY2016-Q3First statedAnnual report
「Revenue was ¥1,404,001 thousand, an increase of ¥150,665 thousand, or 12.0%, from the same period of the previous year.」
Revenue increased 12.0% year on year due to the comprehensive immune cell therapy support service, equipment and materials, staffing services and license revenue.